Browsing by Subject "Cancer hormone therapy"
Now showing items 1-15 of 15
-
Article
Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients with Breast Cancer and One to Nine Infiltrated Nodes: Five-Year Results of the Hellenic Cooperative Oncology Group Randomized HE 10/92 Study
(2004)The present randomized phase III trial was designed to detect a 15% benefit in relapse-free survival (RFS) or overall survival (OS) from the incorporation of adjuvant tamoxifen to the combination of CNF [cyclophosphamide, ...
-
Article
Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer?
(2011)The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays ...
-
Article
-
Article
Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature
(1990)In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...
-
Article
Effects of hormonal treatment on lipids in patients with cancer
(2009)Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels of total cholesterol (TC) and low density lipoprotein cholesterol ...
-
Article
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
(2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
-
Article
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
(2009)Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...
-
Article
Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation
(2005)Purpose: To identify the incidence of prostate cancer associated-systemic inflammatory syndrome (SIS), and to characterize further this entity, we searched our database as well as the medical literature. Methods: We ...
-
Article
-
Article
Metastatic breast carcinoma confined to bone: Portrait of a clinical entity
(2004)BACKGROUND. The current study was performed to study metastatic breast carcinoma that remains confined to bone. METHODS. The medical notes of 2514 breast carcinoma patients who were treated in 2 academic units over a 20-year ...
-
Article
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: Accumulating evidence for synergy, efficacy, and safety
(2006)Patients with metastatic breast cancer receive multiple lines of cytotoxic chemotherapy, with taxane and anthracycline-based regimens being the most active. Anthracyclines carry the risk of significant cardiotoxicity at ...
-
Article
Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: An overview of survival data
(2006)Several chemotherapy and hormonal therapy regimens have been used in advanced endometrial cancer. In this review we have systematically evaluated the available data from randomized trials on survival. We searched MEDLINE, ...
-
Article
Recurrent episodes of recall dermatitis of irradiated breast after LHRH agonist administration
(2011)
-
Article
Response
(2007)
-
Article
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
(2006)Background: Aromatase inhibitors and inactivators have been extensively tested in patients with advanced breast cancer, but it is unclear whether they offer any survival benefits compared with standard hormonal treatment ...